Physician profile
Maan Harb
NPI 1841674827
$3,378.13
in general payments reported to CMS, 2019-2025
19 companies · $706 in 2025
The $706 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70.13 · 2020: $27.49 · 2021: $125 · 2022: $639 · 2023: $1,000 · 2024: $811 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,516.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $867.02 | 2022-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $711.61 | 2022-2025 | |
| Amgen INC. | $513.31 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $228.64 | 2023-2024 | |
| Pfizer INC. | $189.26 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $123.00 | 2021-2024 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $108.47 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $105.50 | 2021-2024 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $95.73 | 2023-2025 | Amvuttra |
| Esperion Therapeutics, INC. | $93.63 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.04 | 2023-2025 | Jardiance |
| Irhythm Technologies, INC. | $73.49 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Novo Nordisk INC | $46.86 | 2024-2025 | Wegovy |
| Heartflow, INC. | $40.21 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $24.69 | 2023 | Opsumit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.18 | 2023 | Dupixent |
| Abbvie INC. | $14.92 | 2022 | |
| Scpharmaceuticals INC. | $14.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maan Harb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.